It was previously shown that MMP-2 and MMP-9 activity is increased by TGFβ1 treatment in a time- and dose-dependent manner in HCC1806 breast cancer cells (Kim et al., 2016). The gene discussed is TGFB1; the disease is breast carcinoma.